| Identification | Back Directory | [Name]
2-Propenamide, N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(5-methoxy-1H-pyrrolo[3,2-b]pyridin-1-yl)-2-pyrimidinyl]amino]phenyl]- | [CAS]
2050906-40-4 | [Synonyms]
BEBT-109
2-Propenamide, N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(5-methoxy-1H-pyrrolo[3,2-b]pyridin-1-yl)-2-pyrimidinyl]amino]phenyl]- | [Molecular Formula]
C27H32N8O3 | [MOL File]
2050906-40-4.mol | [Molecular Weight]
516.59 |
| Hazard Information | Back Directory | [Uses]
BEBT-109 is a potent pan-mutant-selective EGFR inhibitor. BEBT-109 has improved pharmacokinetic properties. BEBT-109 can be used for multiple mutant-EGFR-driven non-small cell lung cancer (NSCLC) research[1]. | [References]
[1] Fan F, et al BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer. Transl Oncol. 2021 Feb;14(2):100961. DOI:10.1016/j.tranon.2020.100961 |
|
|